Homocysteine, Cognitive Functions, and Degenerative Dementias: State of the Art

Simona Luzzi1, Veronica Cherubini1, Lorenzo Falsetti2

  • 1Neurology Unit, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, 60126 Ancona, Italy.

Biomedicines
|November 11, 2022
PubMed

Insights

High homocysteine levels are linked to cognitive decline and dementia. Further research is needed to understand its specific effects on cognitive functions and non-Alzheimer dementias.

Area of Science:

  • Neurology
  • Biochemistry
  • Gerontology

Background:

  • Homocysteine is a known risk factor for cerebrovascular diseases and degenerative dementias.
  • High homocysteine levels (hyperhomocysteinemia) are implicated in cognitive decline, particularly in Alzheimer's disease.

Purpose of the Study:

  • To investigate the impact of homocysteine on specific cognitive functions.
  • To explore the relationship between homocysteine levels and non-Alzheimer dementias.
  • To understand homocysteine's role in cognitive decline pathogenesis and improve diagnostic accuracy.

Main Methods:

  • Review of existing literature on hyperhomocysteinemia and cognitive function.
  • Analysis of studies examining cognitive performance across different domains.
  • Critique of studies relying solely on screening tests for cognitive assessment.

Main Results:

  • The impact of homocysteine on specific cognitive functions remains poorly investigated.
  • The association between hyperhomocysteinemia and non-Alzheimer dementias requires further study.
  • Current research often lacks detailed cognitive profiling, relying on general screening tests.

Conclusions:

  • Understanding homocysteine's effect on specific cognitive domains is crucial.
  • Identifying brain circuits susceptible to homocysteine damage can clarify its pathogenic role.
  • Further research can enhance diagnostic and prognostic implications for dementias.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
625
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
155
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
189
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
245
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
212
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
142